Skip to content
OpenCapital
Get started

Castle Biosciences CSTL EBITDA

EBITDA at other companies

Veracyte logo
VeracyteVCYT
$28.08M+240%
Personalis, Inc. logo
Personalis, Inc.PSNL
-$29.79M-97.2%
NeoGenomics logo
NeoGenomicsNEO
-$1.83M+81.9%
Fulgent Genetics, Inc. logo
Fulgent Genetics, Inc.FLGT
-$28.62M-106%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
-$102.98M-38.6%
Labcorp Holdings logo
Labcorp HoldingsLH
——

Other financials

Income statement

See full
Revenue$83.7M-4.9%
Gross profit$63.1M-11.8%
Operating income-$18.4M+34.1%
Net income-$14.5M+43.8%
EPS (diluted)-$0.49+45.6%

Balance sheet

See full
Cash & equivalents$63.8M-28.9%
Total debt$36.7M+42.1%
Total equity$461.4M+4.8%
Total assets$547.8M+9.2%

Cash flow

See full
Operating cash flow-$22.1M-267%
CapEx$12.5M+163%
Free cash flow-$34.6M-221%

Valuation

See full
Market cap$694.86M+29.9%
Enterprise value$667.82M+41.8%
P/S2×+0.5×

Profitability

See full
Gross margin77.9%-4.1pp
Operating margin-9.8%-30.8pp
Net margin-3.8%-10.2pp
FCF margin1.3%-10.7pp

Returns & leverage

See full
Return on equity-2.8%-10.6pp
Debt / equity0.1×0.0×
Current ratio6.7×-2.6×

Where this comes from

Calculated from Castle Biosciences’s reported figures.

−$18.4Mebit+
$3.9MDepreciation Depletion & Amortization
=-$14.48M

The official record: Castle Biosciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Castle Biosciences's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Castle Biosciences's EBITDA?
Castle Biosciences (CSTL) reported EBITDA of -$14.48M in Q1 2026.
How has Castle Biosciences's EBITDA changed year-over-year?
Castle Biosciences's EBITDA decreased by 888.6% year-over-year, from $1.84M to -$14.48M.
What is the long-term trend for Castle Biosciences's EBITDA?
Over 4 years (2021 to 2025), Castle Biosciences's EBITDA has grown at a -51.4% compound annual growth rate (CAGR), from -$36.67M to -$2.04M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.